Home Cart 0 Sign in  

[ CAS No. 40299-87-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 40299-87-4
Chemical Structure| 40299-87-4
Structure of 40299-87-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 40299-87-4 ]

Related Doc. of [ 40299-87-4 ]

Alternatived Products of [ 40299-87-4 ]

Product Details of [ 40299-87-4 ]

CAS No. :40299-87-4 MDL No. :MFCD06800306
Formula : C6H10BrNO2 Boiling Point : -
Linear Structure Formula :- InChI Key :LLLQAMNGYJQUKK-UHFFFAOYSA-N
M.W : 208.05 Pubchem ID :13996876
Synonyms :

Calculated chemistry of [ 40299-87-4 ]

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.83
Num. rotatable bonds : 2
Num. H-bond acceptors : 2.0
Num. H-bond donors : 0.0
Molar Refractivity : 44.81
TPSA : 29.54 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.87 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.73
Log Po/w (XLOGP3) : -0.43
Log Po/w (WLOGP) : -0.14
Log Po/w (MLOGP) : 0.12
Log Po/w (SILICOS-IT) : 1.21
Consensus Log Po/w : 0.5

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -0.73
Solubility : 39.0 mg/ml ; 0.187 mol/l
Class : Very soluble
Log S (Ali) : 0.27
Solubility : 392.0 mg/ml ; 1.88 mol/l
Class : Highly soluble
Log S (SILICOS-IT) : -1.28
Solubility : 11.0 mg/ml ; 0.0527 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.97

Safety of [ 40299-87-4 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 40299-87-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 40299-87-4 ]

[ 40299-87-4 ] Synthesis Path-Downstream   1~88

  • 1
  • [ 110-91-8 ]
  • [ 22118-09-8 ]
  • [ 40299-87-4 ]
YieldReaction ConditionsOperation in experiment
28% With triethylamine; In dichloromethane; at 0 - 20℃;Inert atmosphere; Under the protection of argon, Weigh morpholine (600 muL, 6.9 mmol) in anhydrous dichloromethane (8 mL), Triethylamine (960 muL, 6.9 mmol) was sequentially added dropwise at 0 C. A solution of 2-bromoacetyl chloride (580 muL, 6.9 mmol) in anhydrous dichloromethane (4 mL), Stir overnight at room temperature. After the reaction was completed, water (15 mL) was added to the reaction solution. Extracted with dichloromethane (15 mL x 2), Washed with saturated sodium bicarbonate (8mL x 2) and saturated sodium chloride (10mL x 1), Dry over anhydrous sodium sulfate and evaporate the solvent under reduced pressure. The residue containing compound 97-1 was used directly in the next step without further reaction.
With triethylamine; In dichloromethane; at -25 - 20℃; for 4.75h;Inert atmosphere; flask is charged with bromoacetyl bromide (25 mL), dichloromethane (500 mL) and mixture is stirred under nitrogen atmosphere. The reaction mixture is cooled to -25C followed by slow addition of morpholine (72.7 mL in 500 mL of DCM) at the same temperature over a period of 30 minutes. The reaction mixture is stirred at -25C for 15 minutes, then allowed to attain room temperature at which it is further stirred for 4 hours. The completion of the reaction is monitored by TLC and reaction mixture is sequentially washed with water (2x250 mL) and brine solution (2x100 mL). The organic solvent is subjected to distillation to afford the title compound.
  • 4
  • [ 40299-87-4 ]
  • [ 14538-16-0 ]
  • [ 38922-43-9 ]
  • [ 23599-20-4 ]
  • 5
  • [ 40299-87-4 ]
  • [ 139-94-6 ]
  • [ 52121-26-3 ]
  • 6
  • [ 110-91-8 ]
  • [ 598-21-0 ]
  • [ 40299-87-4 ]
YieldReaction ConditionsOperation in experiment
100% In dichloromethane; at 0 - 20℃; for 1.5h;Inert atmosphere; General procedure: Amine (2.0 equiv.) was added to stirred solution of bromoacetyl bromide (1.0 equiv.) in DCM (ca. 0.15 M) at 0 C. After 30 min, reaction was warmed to rt, stirred for 1 h, and saturated ammonium chloride solution was added. The mixture was extracted with Et2O (2 x), dried over anhydrous Na2SO4, filtered, and concentrated to dryness.
62% With N-ethyl-N,N-diisopropylamine; In dichloromethane; Step 1 4-(alpha-Bromoacetyl)morpholine To an ice cold solution of morpholine (2.17 g, 24.9 mmol) and diisopropylethylamine (3.21 g, 24.9 mmol) in CH2Cl2 (70 mL) was added a solution of bromoacetyl bromide (5.05 g, 25 mmole) in CH2Cl2 (8 mL) via syringe. The resulting solution was kept at 0 C. for 45 min, then was allowed to warm to room temp. The reaction mixture was diluted with EtOAc (500 mL), sequentially washed with a 1M HCl solution (250 mL) and a saturated NaCl solution (250 mL), and dried (MgSO4) to give the desired product (3.2 g, 62%): 1H-NMR (DMSO-d6) delta 3.40-3.50 (m, 4H), 3.50-3.60 (m, 4H), 4.11 (s, 2H).
62% With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 0 - 20℃; for 0.75h; Step 1. 4-(alpha-Bromoacetyl)morpholine To an ice cold solution of morpholine (2.17 g, 24.9 mmol) and diisopropylethylamine (3.21 g, 24.9 mmol) in CH2Cl2 (70 mL) was added a solution of bromoacetyl bromide (5.05 g, 25 mmole) in CH2Cl2 (8 mL) via syringe. The resulting solution was kept at 0 C. for 45 min, then was allowed to warm to room temp. The reaction mixture was diluted with EtOAc (500 mL), sequentially washed with a 1M HCl solution (250 mL) and a saturated NaCl solution (250 mL), and dried (MgSO4) to give the desired product (3.2 g, 62%): 1H-NMR (DMSO-d6) delta 3.40-3.50 (m, 4H), 3.50-3.60 (m, 4H), 4.11 (s, 2H).
62% With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 0 - 20℃; for 0.75h; To an ice cold solution of morpholine (2.17 g, 24.9 mmol) and diisopropylethylamine (3.21 g, 24.9 mmol) in CH2Cl2 (70 mL) was added a solution of bromoacetyl bromide (5.05 g, 25 mmole) in CH2Cl2 (8 mL) via syringe. The resulting solution was kept at 0 C for 45 min, then was allowed to warm to room temp. The reaction mixture was diluted with EtOAc (500 mL), sequentially washed with a 1M HCl solution (250 mL) and a saturated NaCl solution (250 mL), and dried (MgSO4) to give the desired product (3.2 g, 62%): 1H-NMR (DMSO-d6) ? 3.40-3.50 (m, 4H), 3.50-3.60 (m, 4H), 4.11 (s, 2H).
62% With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 0℃; for 0.75h; A9. General Method for Synthesis of Aryl Anilines via Alkylation of a Nitrophenol Followed by Reduction; [] Step 1.4-(alpha-Bromoacetyl)morpholine: To an ice cold solution of morpholine (2.17 g, 24.9 mmol) and diisopropylethylamine (3.21 g, 24.9 mmol) in CH2Cl2 (70 mL) was added a solution of bromoacetyl bromide (5.05 g, 25 nunole) in CH2Cl2 (8 mL) via syringe. The resulting solution was kept at 0 C for 45 min, then was allowed to warm to room temp. The reaction mixture was diluted with EtOAc (500 mL), sequentially washed with a 1M HCl solution (250 mL) and a saturated NaCl solution (250 mL), and dried (MgSO4) to give the desired product (3.2 g, 62%): 1H-NMR (DMSO-d6) delta 3.40-3.50 (m, 4H), 3.50-3.60 (m, 4H), 4.11 (s, 2H).
54% With triethylamine; In dichloromethane; at -4℃; for 1.5h;Inert atmosphere; Morpholine (9.9 mmoles, 0.87 mL) wasdissolved in CH2Cl2 (0.2 M, 50 mL), Et3N (0.015 moles, 2.07 mL, 1.5 equiv) was added and the mixture was cooled to -4 C. Bromoacetyl bromide (9.9mmoles, 0.86 mL, 1.0 equiv) was then added dropwise and the reaction was allowed to stir at thesame temperature for 1.5 h. The reaction mixture was washed with saturated NH4Cl (2x30 mL)and saturated NaHCO3 (2x30 mL) and then concentrated to dryness. Purification by flashcolumn chromatography (50?80% EtOAc / Hexanes) furnished 1.12 g of the desiredmorpholinoacetyl bromide 27 in 54% yield (un-optimized);
In dichloromethane; at -25℃; for 1.25h; A solution of bromoacetyl bromide (3.0 mL, 0.034 mol) in dichloromethane (240 mL) was cooled to -25 C. A solution of morpholine (9.0 mL, 0.10 mol) in dichloromethane (20 mL) was slowly added over a period of one hour. After the addition was complete, the reaction was stirred at -25 C for 15 minutes and allowed to warm to ambient temperature. Dichloromethane was added, and the resulting solution was washed with water, IN aqueous hydrogen chloride, and brine; dried over magnesium sulfate; EPO <DP n="95"/>filtered; and concentrated under reduced pressure to provide 4-(bromoacetyl)morpholine as a colorless oil.
With triethylamine; 3-Hydroxy-7-(2-morpholin-4-yl-2-oxo-ethoxy)-naphthalene-2-carboxylic acid benzyl ester A mixture of morpholine (2.16 mL, 25 mmol) and anhydrous ether (30 mL) was cooled (-10 C.) and treated drop wise with a solution of bromoacetyl bromide (5.0 g, 25 mmol) in ether (20 mL). Triethyl amine (3.5 mL, 25 mmol) then was added drop wise to the reaction mixture to form a cream colored reaction mixture. The creamy reaction mixture was agitated at about 20 C. for about 6 hours. The reaction solids were isolated and rinsed with ether. The combined ether fractions were concentrated under reduced pressure to afford N-(2-bromoacetyl)-morpholine (3.37 g) as a reddish oil, which was used without further purification.
In tetrahydrofuran; a) 50 g (0.57 mol) of morpholine are added dropwise at 10 C. to a solution of 58 g (0.28 mol) of bromoacetyl bromide in 500 ml THF. After 2 hours, precipitated morpholine hydrobromide is filtered off, the filtrate is concentrated and the residue is distilled in vacuo at 110 C./0.5 mm Hg. 39 g (67%) of bromoacetyl morpholide are obtained as colourless crystals which melt a little above room temperature.
In dichloromethane; at -25℃; for 1.25h; A solution of bromoacetyl bromide (3.0 mL, 0.034 mol) in dichloromethane (240 mL) was cooled to -25 0C. A solution of morpholine (9.0 mL, 0.10 mol) in dichloromethane (20 mL) was slowly added over a period of one hour. After the addition was complete, the reaction was stirred at -25 C for 15 minutes and then allowed to warm to ambient temperature. Dichloromethane was added, and the resulting solution was washed sequentially with water, IN aqueous hydrogen chloride, and brine; dried over magnesium sulfate; filtered; and concentrated under reduced pressure to provide 4- (bromoacetyl)morpholine as a colorless oil
With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 0℃; for 1.5h;Inert atmosphere; General procedure: A solution of diethylamine (0.72 mL, 7.0 mmol) and N,N-diisopropylethylamine (1.22 mL, 7.0 mmol) in dichloromethane (23 mL) was treated with bromoacetyl bromide (0.61 mL, 7.0 mmol) at 0 C. The mixture was stirred for 1.5 h at the same temperature and diluted with water. Extractive workup and evaporation of the volatiles gave N,N-diethyl-2-bromoacetamide (20) (1.17 g, 86% yield) as a yellow oil. The following procedure was the same with that of 4d(84% overall yield from 20).
In dichloromethane; at 0℃; for 1.5h; Compound No. 23a was prepared by dissolving 2-bromoacetyl bromide (0.861 mL, 9.91 mmol) in dichloromethane (100 mL) at 0C, at which point morpholine (1.726 g, 19.82 mmol) in dichloromethane (12 mL) was added slowly at 0 C and stirred for 90 minutes. The reaction mixture was washed with water twice, dried through magnesium sulfate, and concentrated to give 2-bromo-l -morpholinoethanone as a pale-yellow liquid as the desired product. NMR spectroscopy was consistent with the proposed structure.
With triethylamine; In dichloromethane; at 20℃; for 1h; To a solution of 2-bromoacetyl bromide (2.3 g, 11.4 mmol) in 50 mE DCM was added morpholine (1.22 g, 14 mmol) and Et3N (1.9 mE, 13.7 mmol). The reaction was stirred at room temperature for 1 hr. The mixture was washed with water, brine, dried and concentrated to give crude product used directly.
In dichloromethane; at -25℃; for 1.25h; A solution of bromoacetyl bromide (3.0 mL, 0.034 mol) in dichloromethane (240 ML) was cooled TO-25 C. A solution of morpholine (9.0 mL, 0.10 mol) in dichloromethane (20 mL) was slowly added over a period of one hour. After the addition was complete, the reaction was stirred AT-25 C for 15 minutes and allowed to warm to ambient temperature. Dichloromethane was added, and the resulting solution was washed with water, 1N aqueous hydrogen chloride, and brine; dried over magnesium sulfate; filtered; and concentrated under reduced pressure to provide 4- (2-bromoacetyl) morpholine as a colorless oil.
In dichloromethane; at -46 - 20℃; for 1h; Morpholine (1.3 mL, 87 mmol, 2 eq) is added dropwise over 15 min to a cooled solution (-46C)of2-bromoacetyl bromide (0.65 mL, 7.4 mmol, 1 eq) in dry DCM (35 mL). After the addition, the reactionmixture is left to warm up to room temperature and stirred for 1 h. The mixture is washed (sat. NH4Cl,NaHC03 and brine), dried (Na2S04) and concentrated to afford the desired product.

Reference: [1]Tetrahedron Letters,2011,vol. 52,p. 3714 - 3717
[2]Organic Letters,2017,vol. 19,p. 2338 - 2341
[3]Beilstein Journal of Organic Chemistry,2013,vol. 9,p. 1407 - 1413
[4]Biopolymers,2016,p. 726 - 736
[5]Green Chemistry,2014,vol. 16,p. 2252 - 2265
[6]Organic Letters,2011,vol. 13,p. 3138 - 3141
[7]ACS Combinatorial Science,2012,vol. 14,p. 280 - 284
[8]Tetrahedron Letters,2009,vol. 50,p. 5689 - 5691
[9]Patent: US2004/102636,2004,A1
[10]Patent: US2008/269265,2008,A1 .Location in patent: Page/Page column 12
[11]Patent: EP1449834,2004,A2 .Location in patent: Page 19
[12]Patent: EP1042305,2005,B1 .Location in patent: Page/Page column 24-25
[13]Journal of Medicinal Chemistry,1992,vol. 35,p. 1685 - 1701
[14]Bioorganic and Medicinal Chemistry Letters,2014,vol. 24,p. 1122 - 1126
[15]Chemistry - A European Journal,2013,vol. 19,p. 18011 - 18026
[16]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4174 - 4177
[17]Patent: WO2006/86449,2006,A2 .Location in patent: Page/Page column 93-94
[18]Patent: US2002/52343,2002,A1
[19]Patent: US5382585,1995,A
[20]Patent: WO2006/86633,2006,A2 .Location in patent: Page/Page column 65
[21]Chemistry - A European Journal,2009,vol. 15,p. 4538 - 4542
[22]Tetrahedron,2009,vol. 65,p. 6128 - 6134
[23]Tetrahedron,2012,vol. 68,p. 4710 - 4718
[24]Chemistry of Natural Compounds,2013,vol. 48,p. 1047 - 1053
    Khim. Prir. Soedin.,2012,vol. 48,p. 924 - 929,6
[25]Green Chemistry,2013,vol. 15,p. 2727 - 2739
[26]Patent: WO2014/159251,2014,A2 .Location in patent: Page/Page column 132
[27]Journal of Organic Chemistry,2015,vol. 80,p. 8922 - 8928
[28]Patent: US2017/298090,2017,A1 .Location in patent: Paragraph 0141; 0142
[29]Patent: WO2005/32484,2005,A2 .Location in patent: Page/Page column 118-119
[30]Patent: WO2019/7696,2019,A1 .Location in patent: Paragraph 0255
[31]Journal of Heterocyclic Chemistry,2019,vol. 56,p. 2839 - 2852
[32]Journal of Heterocyclic Chemistry,2020
  • 7
  • [ 40299-87-4 ]
  • [ 117953-08-9 ]
  • [ 137184-92-0 ]
  • 8
  • [ 40299-87-4 ]
  • [ 138498-62-1 ]
  • [ 138484-07-8 ]
  • 9
  • [ 40299-87-4 ]
  • demethyl A2 [ No CAS ]
  • 2C60H91N18O23S3(1+)*O4S(2-) [ No CAS ]
  • 10
  • [ 40299-87-4 ]
  • [ 137882-21-4 ]
  • 4'-[2-Methyl-1-(2-morpholin-4-yl-2-oxo-ethyl)-3-oxo-5-propyl-2,3-dihydro-1H-pyrazol-4-ylmethyl]-biphenyl-2-carbonitrile [ No CAS ]
  • [ 137860-76-5 ]
  • 11
  • [ 40299-87-4 ]
  • [ 137860-09-4 ]
  • 4'-[5-Butyl-2-methyl-1-(2-morpholin-4-yl-2-oxo-ethyl)-3-oxo-2,3-dihydro-1H-pyrazol-4-ylmethyl]-biphenyl-2-carbonitrile [ No CAS ]
  • 4'-[3-Butyl-1-methyl-5-(2-morpholin-4-yl-2-oxo-ethoxy)-1H-pyrazol-4-ylmethyl]-biphenyl-2-carbonitrile [ No CAS ]
  • 12
  • [ 40299-87-4 ]
  • [ 137860-28-7 ]
  • 4'-[1-(2-Morpholin-4-yl-2-oxo-ethyl)-3-oxo-5-propyl-2-(2,2,2-trifluoro-ethyl)-2,3-dihydro-1H-pyrazol-4-ylmethyl]-biphenyl-2-carbonitrile [ No CAS ]
  • [ 137860-64-1 ]
  • 13
  • [ 40299-87-4 ]
  • [ 115449-13-3 ]
  • 4-((6S,7S)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-cyclopentyloxyimino]-acetylamino}-2-carboxy-8-oxo-4-oxa-1-aza-bicyclo[4.2.0]oct-2-en-3-ylmethylsulfanyl)-1-(2-morpholin-4-yl-2-oxo-ethyl)-pyridinium; bromide [ No CAS ]
  • 14
  • [ 40299-87-4 ]
  • [ 15898-45-0 ]
  • [ 178674-91-4 ]
  • 15
  • [ 40299-87-4 ]
  • [(S)-2-(4-Hydroxy-phenyl)-1-oxiranyl-ethyl]-carbamic acid tert-butyl ester [ No CAS ]
  • {(S)-2-[4-(2-Morpholin-4-yl-2-oxo-ethoxy)-phenyl]-1-oxiranyl-ethyl}-carbamic acid tert-butyl ester [ No CAS ]
  • 16
  • [ 40299-87-4 ]
  • Cu(II) complex of demethylbleomycin A2 [ No CAS ]
  • [ 104320-77-6 ]
  • 17
  • [ 98-01-1 ]
  • [ 1824-81-3 ]
  • [ 40299-87-4 ]
  • 3-furan-2-yl-3-(6-methyl-pyridin-2-ylamino)-1-morpholin-4-yl-propan-1-one [ No CAS ]
  • 18
  • [ 98-01-1 ]
  • [ 40299-87-4 ]
  • [ 2836-03-5 ]
  • 3-(2-dimethylamino-phenylamino)-3-furan-2-yl-1-morpholin-4-yl-propan-1-one [ No CAS ]
  • 19
  • [ 98-01-1 ]
  • [ 40299-87-4 ]
  • [ 90-04-0 ]
  • 3-furan-2-yl-3-(2-methoxy-phenylamino)-1-morpholin-4-yl-propan-1-one [ No CAS ]
  • 20
  • [ 98-01-1 ]
  • [ 40299-87-4 ]
  • [ 120-71-8 ]
  • 3-furan-2-yl-3-(2-methoxy-5-methyl-phenylamino)-1-morpholin-4-yl-propan-1-one [ No CAS ]
  • 21
  • [ 1824-81-3 ]
  • [ 14371-10-9 ]
  • [ 40299-87-4 ]
  • (E)-3-(6-Methyl-pyridin-2-ylamino)-1-morpholin-4-yl-5-phenyl-pent-4-en-1-one [ No CAS ]
  • 22
  • [ 1824-81-3 ]
  • [ 104-53-0 ]
  • [ 40299-87-4 ]
  • 3-(6-methyl-pyridin-2-ylamino)-1-morpholin-4-yl-5-phenyl-pentan-1-one [ No CAS ]
  • 23
  • [ 1824-81-3 ]
  • [ 40299-87-4 ]
  • [ 104-88-1 ]
  • 3-(4-chloro-phenyl)-3-(6-methyl-pyridin-2-ylamino)-1-morpholin-4-yl-propan-1-one [ No CAS ]
  • 24
  • [ 14371-10-9 ]
  • [ 40299-87-4 ]
  • [ 2836-03-5 ]
  • (E)-3-(2-Dimethylamino-phenylamino)-1-morpholin-4-yl-5-phenyl-pent-4-en-1-one [ No CAS ]
  • 25
  • [ 104-53-0 ]
  • [ 40299-87-4 ]
  • [ 2836-03-5 ]
  • 3-(2-dimethylamino-phenylamino)-1-morpholin-4-yl-5-phenyl-pentan-1-one [ No CAS ]
  • 26
  • [ 40299-87-4 ]
  • [ 2836-03-5 ]
  • [ 104-88-1 ]
  • 3-(4-chloro-phenyl)-3-(2-dimethylamino-phenylamino)-1-morpholin-4-yl-propan-1-one [ No CAS ]
  • 27
  • [ 40299-87-4 ]
  • [ 104-88-1 ]
  • [ 90-04-0 ]
  • N-[3-(2-methoxyphenyl)amino-3-(4-chlorophenyl)-1-oxopropyl]morpholine [ No CAS ]
  • 28
  • [ 40299-87-4 ]
  • [ 104-88-1 ]
  • [ 120-71-8 ]
  • 3-(4-chloro-phenyl)-3-(2-methoxy-5-methyl-phenylamino)-1-morpholin-4-yl-propan-1-one [ No CAS ]
  • 29
  • [ 14371-10-9 ]
  • [ 40299-87-4 ]
  • [ 90-04-0 ]
  • (E)-3-(2-Methoxy-phenylamino)-1-morpholin-4-yl-5-phenyl-pent-4-en-1-one [ No CAS ]
  • 30
  • [ 104-53-0 ]
  • [ 40299-87-4 ]
  • [ 90-04-0 ]
  • 3-(2-methoxy-phenylamino)-1-morpholin-4-yl-5-phenyl-pentan-1-one [ No CAS ]
  • 31
  • [ 14371-10-9 ]
  • [ 40299-87-4 ]
  • [ 120-71-8 ]
  • (E)-3-(2-Methoxy-5-methyl-phenylamino)-1-morpholin-4-yl-5-phenyl-pent-4-en-1-one [ No CAS ]
  • 32
  • [ 104-53-0 ]
  • [ 40299-87-4 ]
  • [ 120-71-8 ]
  • 3-(2-methoxy-5-methyl-phenylamino)-1-morpholin-4-yl-5-phenyl-pentan-1-one [ No CAS ]
  • 33
  • [ 40299-87-4 ]
  • (2R,4S)-2-Benzyl-5-[(R)-3-benzyl-5-(4-hydroxy-benzyl)-2-oxo-pyrrolidin-1-yl]-4-hydroxy-pentanoic acid ((1S,2R)-2-hydroxy-indan-1-yl)-amide [ No CAS ]
  • (2R,4S)-2-Benzyl-5-{(R)-3-benzyl-5-[4-(2-morpholin-4-yl-2-oxo-ethoxy)-benzyl]-2-oxo-pyrrolidin-1-yl}-4-hydroxy-pentanoic acid ((1S,2R)-2-hydroxy-indan-1-yl)-amide [ No CAS ]
  • 34
  • [ 40299-87-4 ]
  • (2R,4S)-5-((3S,5R)-3,5-Dibenzyl-2-oxo-pyrrolidin-1-yl)-4-hydroxy-2-(4-hydroxy-benzyl)-pentanoic acid ((1S,2R)-2-hydroxy-indan-1-yl)-amide [ No CAS ]
  • (2R,4S)-5-((3S,5R)-3,5-Dibenzyl-2-oxo-pyrrolidin-1-yl)-4-hydroxy-2-[4-(2-morpholin-4-yl-2-oxo-ethoxy)-benzyl]-pentanoic acid ((1S,2R)-2-hydroxy-indan-1-yl)-amide [ No CAS ]
  • 35
  • [ 226911-47-3 ]
  • [ 40299-87-4 ]
  • (3R,3aS,4S,4aR,8aS,9aR)-3-Methyl-4-{(E)-2-[6-(2-morpholin-4-yl-2-oxo-ethoxy)-quinolin-2-yl]-vinyl}-decahydro-naphtho[2,3-c]furan-1-one [ No CAS ]
  • 36
  • [ 149747-23-9 ]
  • [ 40299-87-4 ]
  • 2-(5-methyl-4-<i>p</i>-tolyl-4<i>H</i>-[1,2,4]triazol-3-ylsulfanyl)-1-morpholin-4-yl-ethanone [ No CAS ]
  • 37
  • [ 40299-87-4 ]
  • [ 174150-18-6 ]
  • C18H32NO3S(1+)*BF4(1-) [ No CAS ]
  • 38
  • [ 40299-87-4 ]
  • 1-[(2S,3S,5R)-2-carboxy-3-methyl-4,4,7-trioxo-4-thia-1-azabicyclo[3.2.0]hept-3-yl]methyl}-3-(2-morpholin-4-yl-2-oxoethyl)-1H-1,2,3-triazol-3-ium [ No CAS ]
YieldReaction ConditionsOperation in experiment
To a suspension of (2S,3S,5R)-3-methyl-7-oxo-3-(/No.-l,2,3-tnazol-l- ylmethyl)-4-thia-l-azabicyclo-[3.2.0]heptane-2-carboxylic acid 4,4-dioxide (10 g) in dimethylformamide (100 mL) was added N,O-bis(silylacetamide) (10 g) and stirred for 30 min. at 25 to 30C. To the clear solution was added 4- (bromoacetyl)morpholine (14 g) during 20 min. at 25-30 0C under stirring. The reaction mixture was heated to 50 C and stirred at the same temperature for 3 days. Diisopropylether (300 mL) was added to the reaction mixture at 25-30 C and stirred for 1 h. The precipitated mass was separated out and dissolved purified water (100 mL). <n="19"/>Dichloromethane (100 niL) aws added to the resultant clear solution, and stirred for 1 h at 10 to 15 C and the organic layer separated. The aqueous layer was washed with freshly prepared solution of Amberlite LA-2 resin twice, followed by dichloromethane wash. To the aqueous solution, activated carbon (1 g) was added, stirred for 15 min., filtered and washed with purified water (25 mL). The solution was filtered and lyophilized to get the title compound (7 g). The crude product (0.5 g) was purified to obtain the pure title product (0.3 g). 1H NMR (400 MHz, DMSO) Jppm: 1.36 (s, 3H), 3.15 (d, J = 16.0 Hz, IH), 3.43 - 3.67 (m, 9H), 3.97 (s, IH), 5.06 (d, J = 4.1 Hz, IH), 5.37 (d, J = 14.8 Hz, IH), 5.49 (d, J = 14.8 Hz, IH), 5.94 (s, 2H), 8.87 (s, IH), 8.97 (s, IH). Mass m/z: M+l peak at 428.
To a suspension of (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo-[3.2.0]heptane-2-carboxylic acid 4,4-dioxide (10 g) in dimethylformamide (100 mL) was added N,O-bis(silylacetamide) (10 g) and stirred for 30 min. at 25 to 30 C. To the clear solution was added 4-(bromoacetyl)morpholine (14 g) during 20 min. at 25-30 C. under stirring. The reaction mixture was heated to 50 C. and stirred at the same temperature for 3 days. Diisopropylether (300 mL) was added to the reaction mixture at 25-30 C. and stirred for 1 h. The precipitated mass was separated out and dissolved purified water (100 mL). Dichloromethane (100 mL) aws added to the resultant clear solution, and stirred for 1 h at 10 to 15 C. and the organic layer separated. The aqueous layer was washed with freshly prepared solution of Amberlite LA-2 resin twice, followed by dichloromethane wash. To the aqueous solution, activated carbon (1 g) was added, stirred for 15 min., filtered and washed with purified water (25 mL). The solution was filtered and lyophilized to get the title compound (7 g). The crude product (0.5 g) was purified to obtain the pure title product (0.3 g). 1H NMR (400 MHz, DMSO) delta ppm: 1.36 (s, 3H), 3.15 (d, J=16.0 Hz, 1H), 3.43-3.67 (m, 9H), 3.97 (s, 1H), 5.06 (d, J=4.1 Hz, 1H), 5.37 (d, J=14.8 Hz, 1H), 5.49 (d, J=14.8 Hz, 1H), 5.94 (s, 2H), 8.87 (s, 1H), 8.97 (s, 1H). Mass m/z: M+1 peak at 428.
  • 39
  • [ 40299-87-4 ]
  • [ 2058-74-4 ]
  • 1-methyl-3'-(morpholin-4-ylcarbonyl)spiro[indole-3,2'-oxiran]-2(1H)-one [ No CAS ]
  • 1-methyl-3'-(morpholin-4-ylcarbonyl)spiro[indole-3,2'-oxiran]-2(1H)-one [ No CAS ]
  • 40
  • C18H23NO3 [ No CAS ]
  • [ 40299-87-4 ]
  • C24H32N2O5 [ No CAS ]
  • 41
  • [ 110-91-8 ]
  • [ 13094-51-4 ]
  • [ 40299-87-4 ]
  • 42
  • [ 40299-87-4 ]
  • 3-Morpholin-4-yl-2H-benzo[1,4]thiazine 1,1-dioxide [ No CAS ]
  • 43
  • [ 40299-87-4 ]
  • [ 178674-95-8 ]
  • 44
  • [ 40299-87-4 ]
  • (1,1-Dioxo-1,4-dihydro-1λ6-benzo[1,4]thiazin-2-yl)-morpholin-4-yl-methanone [ No CAS ]
  • 45
  • [ 40299-87-4 ]
  • 4-(2-{2-Methyl-5-propyl-4-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-2H-pyrazol-3-yloxy}-ethyl)-morpholine [ No CAS ]
  • 46
  • [ 40299-87-4 ]
  • 2-{2-Methyl-5-propyl-4-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-2H-pyrazol-3-yloxy}-1-morpholin-4-yl-ethanone [ No CAS ]
  • 47
  • [ 40299-87-4 ]
  • 2-{5-Butyl-2-methyl-4-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-2H-pyrazol-3-yloxy}-1-morpholin-4-yl-ethanone [ No CAS ]
  • 48
  • [ 40299-87-4 ]
  • 1-Morpholin-4-yl-2-[5-propyl-4-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-2-(2,2,2-trifluoro-ethyl)-2H-pyrazol-3-yloxy]-ethanone [ No CAS ]
  • 49
  • [ 40299-87-4 ]
  • 1-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-2-{2-methyl-5-propyl-4-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-2H-pyrazol-3-yloxy}-ethanone [ No CAS ]
  • 50
  • [ 40299-87-4 ]
  • [ 3279-07-0 ]
  • 2-(N-morpholinylcarbonyl)methoxy-5-tert-butyl-1-nitrobenzene [ No CAS ]
YieldReaction ConditionsOperation in experiment
33% With potassium carbonate; In DMF (N,N-dimethyl-formamide); at 20℃; for 0.25h; A slurry of 4-tert-butyl-2-nitrophenol (3.9 g, 20 mmol) and K2CO3 (3.31 g, 24 mmol) in DMF (75 mL) was stirred at room temp. for 15 minutes, then a solution of 4-(?-bromoacetyl)morpholine (4.16 g, 20 mmol) in DMF (10 mL) was added. The reaction was allowed to stir at room temp. overnight, then was diluted with EtOAc (500 mL) and sequentially washed with a saturated NaCl solution (4 x 200 mL) and a 1M NaOH solution (400 mL). The residue was purified by flash chromatography (75% EtOAc/25% hexane) to give the nitrobenzene (2.13 g, 33%): 1H-NMR (DMSO-d6) ? 1.25 (s, 9H), 3.35-3.45 (m, 4H), 3.50-3.58 (m, 4H), 5.00 (s, 2H), 7.12 (d, J=8.8 Hz, 1H), 7.50-7.80 (m, 2H).
  • 52
  • [ 40299-87-4 ]
  • [ 106291-80-9 ]
  • [ 776315-11-8 ]
YieldReaction ConditionsOperation in experiment
With sodium hydride; In DMF (N,N-dimethyl-formamide); at 80℃; for 16h; Methyl 4-bromo-3-hydroxybenzoate (71 MG) and 4-(BROMOACETYL) MORPHOLINE (71MG) were combined in DMF (5ml). Sodium hydride (14mg, 60% dispersion in mineral oil) was added and the reaction heated at 80C under nitrogen for 16 hours. The reaction was quenched with water (2ml) and solvent the evaporated in vacuo. The residue was partitioned between water (10ML) and ethyl acetate/chloroform (1: 1, 2X10ML). The organic layers were combined, dried using a hydrophobic filter and evaporated under vacuum. The residue was partially purified by SPE (2g, Si), eluting with a methanol/chloroform gradient (0. 5% to 5%), and the product fractions further purified by mdap, to give methyl 4-BROMO-3- { [2- (4- morpholinyl)-2-oxoethyl]oxy} benzoate as a white SOLID (16MG). LC-MS: Rt 2.72min.
  • 53
  • [ 40299-87-4 ]
  • [ 898817-79-3 ]
  • (11S)-11-isopropyl-3-(2-morpholin-4-yl-2-oxoethoxy)-10,11-dihydro-8H-[1,4]oxazino[4',3':1,2]imidazo[4,5-c]quinolin-6-amine [ No CAS ]
YieldReaction ConditionsOperation in experiment
With caesium carbonate; In N,N-dimethyl-formamide; at 65℃; for 18h; Example 58; (1 IS)-I l-Isorhororhoyl-3-(2-morpholin-4-yl-2-oxoethoxy)-10,l l-dihydro-8H-[l,4] oxazino[4',3': 1 ,2]imidazo[4,5-c]quinolin-6-amine; A solution of (1 l<S)-6-amino-l 1- isopropyl -10,1 l-dihydro-8/f-[l,4]oxazino[4',3':l,2]imidazo[4,5-c]quinolin-3-ol (0.30 g, 1.0 mmol) dissolved in 5 niL of DMF was treated with cesium carbonate (1.0 g, 3.0 mmol) and A- (bromoacetyl)morpholine (0.23 g, 1.1 mmol). After stirring for 18 hours at 65 C, the reaction mixture was concentrated under reduced pressure to give a solid. The solid was dissolved in CH2Cl2 (100 mL) and washed with H2O (100 mL). The organic layer was concentrated under reduced pressure to give a solid. Chromatography (SiO2, 0-15% CMA/CHCI3) gave a white solid which was crystallized from acetonitrile to give 0.18 g of the title compound as white crystals, mp 137-139 C. MS (APCI) m/z 426 (M + H)+. Anal, calcd for C22H27N5O4' 1.5 H2O: C, 58.39; H, 6.68; N, 15.48; Found: C, 58.77; H, 7.36; N, 15.76.
  • 54
  • [ 40299-87-4 ]
  • [ 898818-10-5 ]
  • (11S)-11-methyl-2-(2-morpholin-4-yl-2-oxoethoxy)-10,11-dihydro-8H-[1,4]oxazino[4',3':1,2]imidazo[4,5-c]quinolin-6-amine [ No CAS ]
YieldReaction ConditionsOperation in experiment
With caesium carbonate; In N,N-dimethyl-formamide; at 75℃; Example 55; (HiS)-I l-Methyl-2-(2-morpholin-4-yl-2-oxoethoxy)-10,l l-dihydro-8H- [1 ,4]oxazino[4',3': 1 ,2]imidazo[4,5-c]quinolin-6-amine; A solution of (1 lS)-6-amino-l 1 -methyl- 10, 1 l-dihydro-8H-[l,4]oxazino[4',3':l,2]imidazo[4,5-c]quinolin-2-ol (500 mg, 1.85 mmol) dissolved in 15 mL of DMF was treated with cesium carbonate (1.80 g, 5.55 mmol) and 2-bromo-l- morpholin-4-yl-ethanone (462 mg, 2.03 mmol). After stirring overnight at 75 C, the brown mixture was poured into 150 mL of H2O and stirred for 30 minutes. The reaction mixture was extracted with CHCl3 (3 x 75 mL) and the combined extracts were dried over MgSO4, filtered and concentrated under reduced pressure to give an off-white solid. Chromatography (SiO2, 0-20% CMA/CHCI3) gave an off-white solid which was crystallized from acetonitrile to give 272 mg of the title compound as an off-white solid, mp 226-228 C.1H NMR (500 MHz, OMSO-d6) delta 7.57 (d, J= 9.1 Hz, IH), 7.37 (d, J= 2.6 Hz, IH), 7.14 (dd, J= 2.7, 9.1 Hz, IH), 6.37 (br s, 2H), 5.09 (m, 2H), 4.95 (m, 3H), 4.14 (s, 2H), 3.46- 3.63 (m, 8H), 1.55 (d, J= 6.5 Hz, 3H); 13C NMR (125 MHz, OMSO-d6) delta 166.2, 152.4, 150.3, 145.0, 139.6, 130.8, 127.2, 126.7, 116.6, 114.2, 102.7, 68.2, 66.6, 66.0, 64.6, 49.8, 44.8, 41.5, 19.0; MS (APCI) m/z 398 (M + H)+. Anal, calcd for C20H23N5O4: C, 60.44; H, 5.83; N, 17.62. Found: C, 60.58; H, 5.64; N, 17.67.
  • 55
  • [ 40299-87-4 ]
  • [ 174150-18-6 ]
  • (morpholinecarbamoyl)methyl-[(1R,2S,3R)-2-methoxy-1,7,7-trimethylbicyclo[2.2.1]hept-3-yl] methylsulfonium bromide [ No CAS ]
  • (morpholinecarbamoyl)methyl-[(1R,2S,3R)-2-methoxy-1,7,7-trimethylbicyclo[2.2.1]hept-3-yl] methylsulfonium bromide [ No CAS ]
YieldReaction ConditionsOperation in experiment
In acetone; at 20℃; for 24h; Example 12 (Morpholinecarbamoyl) methyl- [ (1 R, 2S, 3R) -2-methoxy-1, 7, 7trimethyl bicyclo [2. 2.1] hept-3-yl] methylsulfonium bromide (II, R2 + R3 =-(CH2) 2- O-(CH2)2, R4 = Me, R5 = Me) A 3/1 mixture of diastereomeric sulfonium salt was prepared by alkylation of sulfide III (R4, R5 = Me) (2.33 mmol) with 2-bromo-1-morpholin-4-yl- ethanone (2.8 mmol) in acetone (0.5 mL) for 24 hours at room temperature. After washing with hexane and removal of the volatile, the crude oil obtained was used in the epoxidation process without further purification Major isomer (selected signals) : No.H (270 MHz, Cd13) 0.87 (s, 3H), 0.90-1. 70 (m, 3H), 1. 06 (s, 3H), 1.17 (s, 3H), 1. 88 (m, 1H), 2. 03 (d, J 4. 6, 1H), 3. 20 (s, 3H), 3.32-4. 00 (m, 9H), 3.54 (s, 3H), 4.18 (d, J 15.6, 1H)), 5.25 (d, J 7.6, 1H), 6. 63 (d, J 15.6, 1H).
  • 56
  • [ 40299-87-4 ]
  • 7-(2-morpholin-4-yl-2-oxoethoxy)-2-propyl[1,3]thiazolo[4,5-c]quinoline [ No CAS ]
YieldReaction ConditionsOperation in experiment
Under a nitrogen atmosphere, cesium carbonate (4.44 g, 13.6 mmol) was added to a suspension of 2-propyl[l ,3]thiazolo[4,5-c]quinolin-7-ol (2.22 g, 9.09 mmol) in DMF (50 mL), and the reaction mixture was heated at 75 C for 15 minutes. A solution of 4- (bromoacetyl)morpholine (2.26 g, 10.9 mmol) in DMF (10 mL) was added dropwise with stirring. The reaction mixture was stirred at 75 0C for 2.25 hours. The solvent was then removed under reduced pressure at 75 C. The resulting solid was partitioned between dichloromethane (250 mL) and water (250 mL). The organic layer was washed sequentially with water (100 mL) and brine (100 mL), dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting solid was purified by column chromatography using a HORIZON HPFC system (silica cartridge, eluting with 0 to 20% CMA in chloroform), and the purified product was dried under high vacuum to provide 2.84 g of 7-(2-morpholin-4-yl-2-oxoethoxy)-2-propyl[l ,3]thiazolo[4,5-c]quinoline as a light yellow solid. A portion of the product (0.37 g) was recrystallized from tert-butyl methyl ether (40 mL), and the crystals were washed with cold tert-butyl methyl ether and dried in a vacuum oven at 40 0C overnight to provide the following analytical data, mp 133-136 C. Anal, calcd for C19H2iN3O3S: C, 61.44; H, 5.70; N, 11.31. Found: C, 61.26; H, 5.74; N, 11.25.
  • 57
  • [ 40299-87-4 ]
  • 4-nitrobenzyl (1S,5R,6S)-6-((1R)-1-hydroxyethyl)-1-methyl-2-(7-methylthioimidazo[5,1-b]thiazol-2-yl)-1-carbapen-2-em-3-carboxylate [ No CAS ]
  • (1S,5R,6S)-6-((1R)-1-Hydroxyethyl)-1-methyl-2-[7-methylthio-6-(4-morpholinecarbonylmethyl)imidazo-[5,1-bithiazolium-2-yl]-1-1-carbapen-2-em-3-carboxylate [ No CAS ]
  • [ 352306-81-1 ]
YieldReaction ConditionsOperation in experiment
In dichloromethane; N,N-dimethyl-formamide; a 4-Nitrobenzyl (1S,5R,6S)-6-((1R)-1-hydroxy-ethyl)-1-methyl-2-[7-methylthio-6-(4-morpholine-carbonylmethyl)imidazo[5,1-b]thiazolium-2-yl]-1-carbapen-2-em-3-carboxylate bromide 4-Nitrobenzyl (1S,5R,6S)-6-((1R)-1-hydroxyethyl)-1-methyl-2-(7-methylthioimidazo[5,1-b]thiazol-2-yl)-1-carbapen-2-em-3-carboxylate (100 mg) was dissolved in 1 ml of dichloromethane and 1 ml of DMF. 4-Bromoacetylmorpholine (412 mg) was added to the solution. The mixture was stirred at room temperature for 4 days. The solvent was removed by distillation under the reduced pressure. The residue was purified by column chromatography on Sephadex LH-20 (chloroform:methanol =1:1) to prepare 126 mg of 4-nitrobenzyl (1S,5R,6S)-6-((1R)-1-hydroxyethyl)-1-methyl-2-[7-methylthio-6-(4-morpholinecarbonylmethyl)imidazo[5,1-b]thiazolium-2-yl]-1-carbapen-2-em-3-carboxylate bromide as a crude product.
  • 58
  • [ 40299-87-4 ]
  • [ 252871-26-4 ]
  • [ 252872-12-1 ]
YieldReaction ConditionsOperation in experiment
41 mg (67%) With potassium carbonate; In ethyl acetate; N,N-dimethyl-formamide; Example 135 (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl N-[(1S,2R)-1-benzyl-3-((cyclopentyloxy)[3-(2-morpholino-2-oxoethoxy)phenyl]sulfonylamino)-2-hydroxypropyl]carbamate. (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-3-(cyclopentyloxy)[(3-hydroxyphenyl)sulfonyl]amino-2-hydroxypropyl)carbamate (0.09 mmol, 50 mg) was combined with 2-bromo-1-morpholino-1-ethanone (0.09 mmol, 18 mg) and potassium carbonate (0.26 mmol, 36 mg), and stirred in anhydrous DMF (1 mL) under nitrogen for 15 hours at room temperature. The reaction was concentrated to a residue, dissolved in ethyl acetate, washed in distilled water and brine, and dried over magnesium sulfate. The dried solution was then concentrated and purified by silica gel flash chromatography (1:1 hexanes/ethyl acetate) to provide 41 mg (67%) of a white solid. Rf=0.1 (1: 1 hexanes/ethyl acetate); H1-NMR (CDCl3): delta7.47 (2H,m), 7.38 (1H,m), 7.32-7.14 (7H,m), 5.64 (1H,s), 5.03 (2H,m), 4.91-4.76 (1H,m), 4.78 (2H,s), 3.98-3.89 (2H,m), 3.89-3.77 (2H,m), 3.74-3.63 (8H,m), 3.63-3.52 (2H,m), 3.15 (1H,br.s), 3.08-2.98 (2H,m), 2.98-2.84 (3H,m), 2.84-2.74 (1H,m), 1.89-1.71 (4H,m), 1.71-1.49 (4H,m). MS (ESI): M+H=704.
  • 59
  • [ 436851-81-9 ]
  • [ 40299-87-4 ]
  • 2-({6-[4-(2-morpholin-4-yl-2-oxoethyl)piperazin-1-yl]pyrimidin-4-yl}amino)-1,3-thiazole-5-carbonitrile [ No CAS ]
YieldReaction ConditionsOperation in experiment
With N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; 2-({6-[4-(2-Morpholin-4-yl-2-oxoethyl)piperazin-1-yl]pyrimidin-4-yl }amino)-1,3-thiazole-5-carbonitrile (12-5) 2-[(6-Piperazin-1-ylpyrimidin-4-yl)amino]-1,3-thiazole-5-carbonitrile 12-3 (0.10 g, 0.35 mmol) and diisopropylethylamine (0.049 g, 0.38 mmol) were dissolved in DMF. After cooling to 0 C., a DMF solution of 4-(bromoacetyl) morpholine 12-4 (0.08 g, 0.38 mmol) was added slowly via addition funnel. The product was purified on a C18 preparative LC column and isolated via lyophilization. Hi-Res MS: calc: 415.1655 found: 415.1663. 1H-NMR (CD3OD): 8.49 ppm (s, 1H); 8.03 ppm (s, 1H); 6.27 ppm (s, 1H); 4.34 ppm (s, 2H); 3.70 ppm (m, 4H); 3.65 ppm (m, 4H); 3.42 ppm (t, 2H); 3.33 ppm (m, 6H).
  • 60
  • [ 40299-87-4 ]
  • [ 70080-54-5 ]
  • 4-[2-(4-morpholinyl)-2-oxoethoxy]-alpha-oxobenzeneacetic acid ethyl ester [ No CAS ]
YieldReaction ConditionsOperation in experiment
In N-methyl-acetamide; EXAMPLE 254 Preparation of 4-[2-(4-morpholinyl)-2-oxoethoxy]-alpha-oxobenzeneacetic acid ethyl ester A mixture of 4-hydroxy-alpha-oxobenzeneacetic acid ethyl ester (0.71 g) in dimethylformamide (7 mL) under argon was treated with 55% sodium hydride (0.16 g), stirred for 15 minutes and then 4-(bromoacetyl)morpholine (0.76 g) in dimethylformamide (5 mL) was added. The mixture was stirred at room temperature for 18 hours and worked up as in Example 20. The crude product was purified by HPLC (toluene-hexane; 3:1) and then crystallized twice from ethyl acetate-hexane to provide 0.76 g of 4-[2-(4-morpholinyl)-2-oxoethoxy]-alpha-oxobenzeneacetic acid ethyl ester, mp 103-106 C. Analysis Calculated for C16 H19 NO6: C, 59.81; H, 5.96; N, 4.36. Found: C, 59.59; H, 6.00; N, 4.23.
  • 61
  • [ 40299-87-4 ]
  • [ 153874-73-8 ]
  • [ 153874-74-9 ]
YieldReaction ConditionsOperation in experiment
In water; N,N-dimethyl-formamide; b) 0.3 g (38 mmol) of lithium hydride is added in portions to a solution of 5.0 g (25 mmol) of 6-ethyl-[1,2,5]oxadiazolo[3,4-d]pyrimidine-5,7(4H,6H)-dione-1-oxide in 150 ml of DMF. The mixture is heated at 60 C. for 30 minutes and a solution of 8.0 g (38 mmol) of bromoacetyl morpholide in 50 ml of DMF is then added dropwise. After a further 90 minutes at 60 C., the DMF is largely removed by distillation in a rotary evaporator, and the residue is treated with water and extracted with ethyl acetate. The ethyl acetate extract is concentrated until it begins to crystallise and 3.0 g (37%) of 6-ethyl-4-morpholinocarbonylmethyl-[1,2,5]oxadiazolo-[3,4-d]pyrimidine-5,7(4H,6H)-dione-1-oxide are obtained. M.p. 205 C.
  • 62
  • [ 40299-87-4 ]
  • [ 129473-23-0 ]
  • [ 129473-15-0 ]
  • 4-[ 5-chloro-2-(4-methylphenyl)-4-quinolyl]oxyacetyl}morpholine [ No CAS ]
YieldReaction ConditionsOperation in experiment
With potassium carbonate; In chloroform; ethyl acetate; butanone; Example 8 <strong>[40299-87-4]4-(2-Bromoacetyl)morpholine</strong> (7.9 g) in 2-butanone (50 cc) is added to a stirred suspension of a mixture (10 g) of 5-chloro-2-(4-methylphenyl)-4-quinolone and 7-chloro-2-(4-methylphenyl)-4-quinolone and anhydrous potassium carbonate (10.2 g) in 2-butanone (250 cc). The mixture is heated to reflux for 15 hours and cooled to room temperature (approximately 20 C.), the insoluble matter is removed by filtration and the 2-butanone is evaporated off under reduced pressure. The residue is taken up with water (200 cc) and the aqueous phase is extracted with methylene chloride (3*100 cc). The organic phase is separated after settling has taken place, dried and evaporated under reduced pressure. After the residue has been chromatographed twice on silica gel, the first time using a chloroform/ethyl acetate mixture (70:30 by volume) and the second time using a chloroform/ethyl acetate mixture (80:20 by volume) as eluant, the solid obtained is recrystallized in ethyl acetate. 4-[ 5-chloro-2-(4-methylphenyl)-4-quinolyl]oxyacetyl}morpholine (2 g), m.p. 170 is thereby obtained.
  • 63
  • [ 40299-87-4 ]
  • [ 905974-23-4 ]
  • 3-(2-morpholin-4-yl-2-oxoethoxy)-10,11-dihydro-8H-[1,4]oxazino[4',3':1,2]imidazo[4,5-c]quinolin-6-amine [ No CAS ]
YieldReaction ConditionsOperation in experiment
With caesium carbonate; In N,N-dimethyl-formamide; at 90℃; A glass vial was charged with 4-(bromoacetyl)morpholine (0.05 g, 0.26 mmol, 1.1 eq), 6-amino-10,l l-dihydro-8H-[l,4]oxazino [4',3':l,2]imidazo[4,5-c]quinolin-3-ol (0.06 g, 0.23 mmol), DMF (3 mL), and cesium carbonate (0.42 g, 1.3 mmol, 5 eq). The reaction mixture was heated at 90 0C overnight. The reaction was quenched with 30 mL water to provide an off-white precipitate. The solid was collected by vacuum filtration and recrystallized from acetonitrile to provide 0.011 g of 3-(2-morpholin-4-yl-2-oxoethoxy)- 10,l l-dihydro-8H-[l54]oxazino[4'33':l,2]imidazo[4,5-c]quinolin-6-amine, mp 204-206 0C.
  • 64
  • [ 40299-87-4 ]
  • [ 3279-07-0 ]
  • [ 228401-20-5 ]
YieldReaction ConditionsOperation in experiment
33% With potassium carbonate; In N,N-dimethyl-formamide; Step 2 2-(N-Morpholinylcarbonyl)methoxy-5-tert-butyl-1-nitrobenzene A slurry of 4-tert-butyl-2-nitrophenol (3.9 g, 20 mmol) and K2CO3 (3.31 g, 24 mmol) in DMF (75 mL) was stirred at room temp. for 15 minutes, then a solution of 4-(alpha-bromoacetyl)morpholine (4.16 g, 20 mmol) in DMF (10 mL) was added. The reaction was allowed to stir at room temp. overnight, then was diluted with EtOAc (500 mL) and sequentially washed with a saturated NaCl solution (4*200 mL) and a 1M NaOH solution (400 mL). The residue was purified by flash chromatography (75% EtOAc/25% hexane) to give the nitrobenzene (2.13 g, 33%): 1H-NMR (DMSO-d6) delta 1.25 (s, 9H), 3.35-3.45 (m, 4H), 3.50-3.58 (m, 4H), 5.00 (s, 2H), 7.12 (d, J=8.8 Hz, 1H), 7.50-7.80 (m, 2H).
33% Step 2. 2-(N-Morpholinylcarbonyl)methoxy-5-tert-butyl-1-nitrobenzene A slurry of 4-tert-butyl-2-nitrophenol (3.9 g, 20 mmol) and K2CO3 (3.31 g, 24 mmol) in DMF (75 mL) was stirred at room temp. for 15 minutes, then a solution of 4-(alpha-bromoacetyl)morpholine (4.16 g, 20 mmol) in DMF (10 mL) was added. The reaction was allowed to stir at room temp. overnight, then was diluted with EtOAc (500 mL) and sequentially washed with a saturated NaCl solution (4*200 mL) and a 1M NaOH solution (400 mL). The residue was purified by flash chromatography (75% EtOAc/25% hexane) to give the nitrobenzene (2.13 g, 33%): 1H-NMR (DMSO-d6) delta 1.25 (s, 9H), 3.35-3.45 (m, 4H), 3.50-3.58 (m, 4H), 5.00 (s, 2H), 7.12 (d, J=8.8 Hz, 1H), 7.50-7.80 (m, 2H).
33% Step 2.2-(N-Morpholinylcarbonyl)methoxy-5-tert-butyl-1-nitrobenzene; A slurry of 4-tert-butyl-2-nitrophenol (3.9 g, 20 mmol) and K2CO3 (3.31 g, 24 mmol) in DMF (75 mL) was stirred at room temp. for 15 minutes, then a solution of 4-(alpha-bromoacetyl)morpholine (4.16 g, 20 mmol) in DMF (10 mL) was added. The reaction was allowed to stir at room temp. overnight, then was diluted with EtOAc (500 mL) and sequentially washed with a saturated NaCl solution (4 x 200 mL) and a 1M NaOH solution (400 mL). The residue was purified by flash chromatography (75% EtOAc/25% hexane) to give the nitrobenzene (2.13 g, 33%): 1H-NMR (DMSO-d6) delta 1.25 (s, 9H), 3.35-3.45 (m, 4H), 3.50-3.58 (m, 4H), 5.00 (s, 2H), 7.12 (d, J=8.8 Hz, 1H), 7.50-7.80 (m, 2H).
  • 65
  • [ 40299-87-4 ]
  • [ 422564-77-0 ]
  • [ 1023731-41-0 ]
  • 66
  • [ 40299-87-4 ]
  • [ 422564-81-6 ]
  • [ 1023731-53-4 ]
  • 67
  • [ 40299-87-4 ]
  • [ 82075-97-6 ]
  • [ 1023731-39-6 ]
  • 68
  • [ 40299-87-4 ]
  • [ 850068-95-0 ]
  • [ 850068-96-1 ]
YieldReaction ConditionsOperation in experiment
Under a nitrogen atmosphere, a mixture OF 2-ETHYL-1- (2-METHYLPROPYL)-1H imidazo [4,5-c] quinolin-7-ol (1.97 g, 7.31 mmol), solid cesium carbonate (4.77 g, 14.6 mmol), and DMF (105 mL) was heated at 85 C for 30 minutes. The heat was removed, and a solution of 4- (2-bromoacetyl) morpholine (1.83 g, 8.77 mmol) in DMF (20 mL) was added over a period of 12 minutes. The reaction was heated at 85 C for 3.5 hours, and methanol (1 mL) was then added. The reaction mixture was filtered to remove solids, and the filtrate was concentrated under reduced pressure to provide an orange oil. The oil was triturated with ethyl acetate and water to provide a fluffy, white solid that was isolated by filtration. The filtrate was concentrated under reduced pressure to provide a solid that was stirred with diethyl ether and water and isolated by filtration. The two solids were combined and dried in a vacuum oven at 60 C to provide 2.75 g OF 2-ETHYL-1-(2- METHYLPROPYL)-7- (2-MORPHOLIN-4-YL-2-OXOETHOXY)-LH-IMIDAZO [4,5-c] quinoline as a yellow semi-solid.
  • 69
  • [ 40299-87-4 ]
  • [ 100-52-7 ]
  • [ 16619-19-5 ]
  • 70
  • [ 40299-87-4 ]
  • [ 7597-18-4 ]
  • [ 1193109-31-7 ]
  • 71
  • [ 40299-87-4 ]
  • [ 1160754-97-1 ]
  • [ 1160755-07-6 ]
YieldReaction ConditionsOperation in experiment
With caesium carbonate; In N,N-dimethyl-formamide; at 20℃; for 0.666667h; 2-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-1-morpholin-4-yl-ethanone (R)-tert-butyl 5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate (Intermediate M) (446 mg, 0.565 mmol) is dissolved in DMF (10 ml) and Cs2CO3 (368 mg, 1.131 mmol) and 2-bromo-1-morpholinethanone (118 mg, 0.565 mmol) are added. The reaction is stirred at room temperature for 40 minutes, then diluted with water (20 ml) and extracted with EtOAc (2*50 ml). The organic layers are dried over MgSO4 and the solvent concentrated in vacuo to give a clear oil. Purification by chromatography on a Waters 3000 prep HPLC system (Microsorb C18 Water/MeCN +0.1% TFA) yields a clear oil, which is dissolved in dioxane (4 ml) and treated with 4 M HCl in dioxane (4 ml) and stirred at room temperature for 4 days. Concentration in vacuo affords a white foam which is dissolved in MeOH (3 ml) and loaded onto a 10 g SCX-2 cartridge which is washed with MeOH (60 ml) and 7M NH3 in MeOH (60 ml). The NH3 fractions are combined and concentrated in vacuo to give the title compound as a colourless oil; [M+H]+ 322
With caesium carbonate; In N,N-dimethyl-formamide; at 20℃; for 0.666667h; (R)-tert-butyl 5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate (Intermediate M) (446 mg, 0.565 mmol) is dissolved in DMF (10 ml) and Cs2CO3 (368 mg, 1.131 mmol) and 2-bromo-1-morpholinethanone (118 mg, 0.565 mmol) are added. The reaction is stirred at room temperature for 40 minutes, then diluted with water (20 ml) and extracted with EtOAc (2*50 ml). The organic layers are dried over MgSO4 and the solvent concentrated in vacuo to give a clear oil. Purification by chromatography on a Waters 3000 prep HPLC system (Microsorb C18 Water/MeCN+0.1% TFA) yields a clear oil, which is dissolved in dioxane (4 ml) and treated with 4 M HCl in dioxane (4 ml) and stirred at room temperature for 4 days. Concentration in vacuo affords a white foam which is dissolved in MeOH (3 ml) and loaded onto a 10 g SCX-2 cartridge which is washed with MeOH (60 ml) and 7M NH3 in MeOH (60 ml). The NH3 fractions are combined and concentrated in vacuo to give the title compound as a colorless oil; [M+H]+ 322.
  • 72
  • [ 110-86-1 ]
  • [ 40299-87-4 ]
  • [ 769-42-6 ]
  • [ 100-52-7 ]
  • [ 1207997-24-7 ]
  • 73
  • [ 110-86-1 ]
  • [ 40299-87-4 ]
  • [ 769-42-6 ]
  • [ 100-52-7 ]
  • Br(1-)*C11H15N2O2(1+) [ No CAS ]
  • [ 54459-73-3 ]
  • 74
  • [ 40299-87-4 ]
  • [ 90-02-8 ]
  • [ 77509-76-3 ]
  • 75
  • phosphorous acid ethyl ester di-<i>o</i>-tolyl ester [ No CAS ]
  • [ 40299-87-4 ]
  • [ 1190210-98-0 ]
  • 76
  • [ 851348-76-0 ]
  • [ 40299-87-4 ]
  • [ 1190211-00-7 ]
  • 77
  • [ 40299-87-4 ]
  • [ 1190210-96-8 ]
  • [ 1190210-99-1 ]
  • 78
  • [ 40299-87-4 ]
  • [ 4712-55-4 ]
  • [ 1190210-95-7 ]
  • 81
  • [ 40299-87-4 ]
  • (R)-tert-butyl 5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate [ No CAS ]
  • [ 1160755-05-4 ]
YieldReaction ConditionsOperation in experiment
With hydrogenchloride; caesium carbonate; In 1,4-dioxane; methanol; N,N-dimethyl-formamide; 2-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-1-morpholin-4-yl-ethanone (R)-tert-butyl 5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate (Intermediate M) (446 mg, 0.565 mmol) is dissolved in DMF (10 ml) and Cs2CO3 (368 mg, 1.131 mmol) and 2-bromo-1-morpholinethanone (118 mg, 0.565 mmol) are added. The reaction is stirred at room temperature for 40 minutes, then diluted with water (20 ml) and extracted with EtOAc (2*50 ml). The organic layers are dried over MgSO4 and the solvent concentrated in vacuo to give a clear oil. Purification by chromatography on a Waters 3000 prep HPLC system (Microsorb C18 Water/MeCN+0.1% TFA) yields a clear oil, which is dissolved in dioxane (4 ml) and treated with 4 M HCl in dioxane (4 ml) and stirred at room temperature for 4 days. Concentration in vacuo affords a white foam which is dissolved in MeOH (3 ml) and loaded onto a 10 g SCX-2 cartridge which is washed with MeOH (60 ml) and 7M NH3 in MeOH (60 ml). The NH3 fractions are combined and concentrated in vacuo to give the title compound as a colorless oil; [M+H]+ 322.
  • 82
  • 2-isopropyl-3-methoxy-2H-indazole [ No CAS ]
  • [ 40299-87-4 ]
  • [ 1309979-77-8 ]
  • 83
  • [ 40299-87-4 ]
  • [ 1227927-45-8 ]
  • [ 1309979-86-9 ]
  • 84
  • [ 40299-87-4 ]
  • [ 342-86-9 ]
  • [ 1309979-89-2 ]
  • 85
  • [ 40299-87-4 ]
  • [ 2926-29-6 ]
  • [ 1315549-93-9 ]
YieldReaction ConditionsOperation in experiment
52% In N,N-dimethyl acetamide; at 70℃; for 72h;Inert atmosphere; 2-bromo-1-morpholinoethanone (202 mg, 0.97 mmol, 1.0 equiv.) and sodium trifluoromethanesulfinate (311 mg, 1.94 mmol, 2.0 equiv.) were dissolved in DMA (2 mL), and the mixture was stirred for 3 days at 70 C under N2. The reaction was cooled to 60 C, concentrated to dryness, diluted with ether, filtered over Celite, and concentrated to dryness again. The resulting residue was purified by automated flash chromatography (10 g silica column, 50% EtOAc/hex) to afford 2-(trifluoromethanesulfonyl)-1-morpholinoethanone 11 (133 mg, 0.51 mmol, 52%) as a white solid.
  • 87
  • [ 40299-87-4 ]
  • [ 1370463-23-2 ]
  • 88
  • [ 40299-87-4 ]
  • [ 1370463-27-6 ]
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 40299-87-4 ]

Bromides

Chemical Structure| 42802-94-8

[ 42802-94-8 ]

4-(2-Bromoethyl)morpholine hydrobromide

Similarity: 0.71

Chemical Structure| 89583-07-3

[ 89583-07-3 ]

4-(2-Bromoethyl)morpholine

Similarity: 0.71

Chemical Structure| 5468-77-9

[ 5468-77-9 ]

2-Bromo-N,N-dimethylacetamide

Similarity: 0.69

Chemical Structure| 1048664-14-7

[ 1048664-14-7 ]

1-(4-(2-Bromoethyl)piperazin-1-yl)ethanone hydrobromide

Similarity: 0.63

Chemical Structure| 1138445-61-0

[ 1138445-61-0 ]

2-Bromo-N-hexadecylacetamide

Similarity: 0.56

Amides

Chemical Structure| 1696-20-4

[ 1696-20-4 ]

1-Morpholinoethanone

Similarity: 0.80

Chemical Structure| 51068-78-1

[ 51068-78-1 ]

2-Hydroxy-1-morpholinoethanone

Similarity: 0.76

Chemical Structure| 5468-77-9

[ 5468-77-9 ]

2-Bromo-N,N-dimethylacetamide

Similarity: 0.69

Chemical Structure| 1440-61-5

[ 1440-61-5 ]

4-(2-Chloroacetyl)morpholine

Similarity: 0.68

Chemical Structure| 109-11-5

[ 109-11-5 ]

Morpholin-3-one

Similarity: 0.66

Related Parent Nucleus of
[ 40299-87-4 ]

Morpholines

Chemical Structure| 1696-20-4

[ 1696-20-4 ]

1-Morpholinoethanone

Similarity: 0.80

Chemical Structure| 51068-78-1

[ 51068-78-1 ]

2-Hydroxy-1-morpholinoethanone

Similarity: 0.76

Chemical Structure| 42802-94-8

[ 42802-94-8 ]

4-(2-Bromoethyl)morpholine hydrobromide

Similarity: 0.71

Chemical Structure| 4394-85-8

[ 4394-85-8 ]

Morpholine-4-carbaldehyde

Similarity: 0.71

Chemical Structure| 89583-07-3

[ 89583-07-3 ]

4-(2-Bromoethyl)morpholine

Similarity: 0.71